There Could Be a Chlamydia Vaccine In the Coming Years, A Promising New Study Suggests
The first-ever human trial of a genital-chlamydia vaccine suggests that it is safe and effective, according to a new study published in the Lancet. U.S. sexually transmitted illness diagnoses have reached new highs for the past four years in a row, and chlamydia is responsible for the bulk of those infections: 1.7 million cases were diagnosed in 2017 alone, according to the U.S. Centers for Disease Control and Prevention, compared to about 550,000 cases of gonorrhea, 40,000 cases of HIV and 30,000 cases of syphilis. Globally, the problem is even more widespread: about 127 million cases were diagnosed in 2016, according to the World Health Organization. But despite its prevalence, chlamydia can be difficult to diagnose because many people do not show symptoms. That means people may unknowingly pass it on to partners or delay treatment for themselves. But just because it doesn’t always cause obvious symptoms doesn’t mean chlamydia isn’t harmful; over time, the infection raises the risk of infertility and chronic pelvic pain, especially for women, and can make people more susceptible to other infections, including HIV. Of course, condoms can prevent the transmission of chlamydia, as well as other STIs, but research suggests people do not use them consistently. “To have a real public-health impact, you need to have something that just prevents infection, and that’s what a vaccine would be designed to do,” says Lancet study co-author Robin Shat...
Publication date: Available online 7 July 2020Source: The American Journal of SurgeryAuthor(s): Kurt S. Schultz, Susanna W.L. de Geus, Teviah E. Sachs, Ryan B. Morgan, Sing Chau Ng, David McAneny, Jennifer F. Tseng
The objectives of this paper are the presentation of a sample of patients with PC undergoing treatment with androgen deprivation therapy (ADT) in usual clinical practice and the determination of parameters associated with the development of resistance to castration (CRPC). MATERIAL AND METHODS: Multicenter, observational, retrospective study that analyzes patients treated with ADT from January 2016 to January 2017. Descriptive analysis of the most relevant clinical variables and univariante analysis and progression times by Kaplan-Meier test. RESULTS: Sample of 952 patients. At PC diagnosis median age 74 years. Med...
CONCLUSIONS: We concluded that despite the fact that the plasmacytoid variant of BC is rare, it is important to take into account the pathologic and clinical features of this tumor in order to manage the optimal treatment of this poor prognosis cancer. PMID: 32633253 [PubMed - in process]
HI there, anyone can suggest the top fellowships with mostly EMG (no EEG, no pain, no sleep)? Is there a place training mostly in EMG? Goal to be independent in 1 year (for private practice).
Publication date: Available online 8 July 2020Source: Journal of Contextual Behavioral ScienceAuthor(s): Amanda Davey, Joseph Chilcot, Elizabeth Driscoll, Lance M. McCracken
Patient age, breast density, and radiation exposure are among the strongest,...Read more on AuntMinnie.comRelated Reading: Earlier breast screening benefits women with childhood cancer Interval breast cancers have unique characteristics Breast imagers can help identify women for genetic testing Women want breast cancer risk info from radiologists Many women at risk for breast cancer don't take action
CONCLUSION: To address flaws in conceptualisation and the resulting gaps in knowledge, we suggest a definition and a theoretical framework that are suited to allow heterogeneity in the field, but enables the development of sound interventions, as well as facilitate the interpretation of intervention effectiveness. PMID: 32631110 [PubMed - in process]
Publication date: Available online 7 July 2020Source: SeizureAuthor(s): Yuval Shafrir
Publication date: 30 August 2020Source: International Journal of Pharmaceutics, Volume 586Author(s): Joo Young Lee, Young-um Jo, Heejun Shin, Jonghwan Lee, Soon Uk Chae, Soo Kyung Bae, Kun Na
CONCLUSIONS: Levels of TF-positive EVs, D-dimer and sP-selectin are able to discriminate between unprovoked VTD patients not related to cancer and cancer patients not associated with VTD. These results could lead to the application of EVs as biomarkers of both diseases.Key Messages: Circulating EVs, specifically TF-positive EVs, in combination with plasmatic markers of hypercoagulable states, such as D-dimer, sP-selectin and antigen TF, are able to discriminate between cancer patients without thrombosis and patients with unprovoked VTD. Research fields could be opened. Future studies will assess if these biomarkers togethe...
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Centers for Disease Control and Prevention (CDC) | Chlamydia | Chronic Pain | Clinical Trials | Girls | Health | Infertility | International Medicine & Public Health | Pain | Reproduction Medicine | STDs | Study | Syphilis | Vaccines | WHO | Women